Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma

Michael J. Overman, Harris S. Soifer, Aaron Joel Schueneman, Joe Ensor, Volkan Adsay, Burcu Saka, Nastaran Neishaboori, Robert A. Wolff, Huamin Wang, Catherine A. Schnabel, Gauri Varadhachary

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Background: Ampullary adenocarcinoma is a rare gastrointestinal cancer associated with diverse outcomes due to clinical and pathological heterogeneity. Standardized methods to better prognosticate and inform therapeutic selection for ampullary adenocarcinoma are needed. This study explored the novel use and potential prognostic utility of a 92-gene cancer classifier in ampullary adenocarcinomas. Methods: In this prospectively-defined, blinded study of ampullary adenocarcinoma [N =54; stage T3 or higher (57 %); Grade III (44 %); Node positive (55 %)], the performance of a 92-gene classifier was examined to predict the ampullary subtype that was derived from histomorphological examination of resected ampullary samples. Outcome data for relapse-free survival (RFS) and overall survival (OS) were plotted to compare the prognostic utility of histological subtyping, histomolecular phenotyping, and the 92-gene classifier. Multivariate analysis was used to determine clinicopathological variables that were independently associated with overall survival. Results: The 92-gene classifier demonstrated sensitivities and specificities of 85 % [95 % CI, 66-94] and 68 % [95 % CI, 48-84] and 64 % [95 % CI, 46-79] and 88 % [95 % CI, 70-98] for the pancreaticobiliary and intestinal histological subtypes, respectively. For the 92-gene classifier, improved outcomes were observed for the intestine versus the pancreaticobiliary prediction (median OS 108.1 v 36.4 months; HR, 2.17; 95 % CI, 0.98 to 4.79; P = 0.05). Similar results were seen for ampullary adenocarcinoma stratification by histological subtype (P = 0.04) and histomolecular phenotype (P = 0.02). Within poorly differentiated ampullary adenocarcinomas only the 92-gene classifier demonstrated statistically significant differences in RFS and OS (P < 0.05). Conclusions: Prognostic stratification of ampullary adenocarcinoma was similar for the 92-gene classifier, histological subtype, and histomolecular phenotype. The 92-gene classifier provides an unbiased standardized molecular-based approach to stratify ampullary tumors.

Original languageEnglish (US)
Article number668
JournalBMC Cancer
Issue number1
StatePublished - Aug 22 2016


  • 92-gene assay
  • Adenocarcinoma
  • Ampullary
  • Biomarker
  • Gene expression profiling
  • Prognostic
  • Subclassification

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research


Dive into the research topics of 'Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma'. Together they form a unique fingerprint.

Cite this